Gene therapy, considered to be the most efficient and sometimes only treatment option for many severe and life-threatening diseases, is shifting to more common indications with higher numbers of patients including Parkinson’s and Alzheimer’s disease. This is where the new ELEVECTA® AAV producer cell lines come into play. ELEVECTA® is a revolutionary technology that enables viral vector manufacturing in an industry-standard, scalable suspension format.

Based on genetic data, a new diagnostic algorithm can differentiate between five different rheumatic diseases.

Oxford-based Evox Therapeutics appoints Sonya Montgomery in the newly formed position of Chief Medical Officer.

Novo Holdings leads the current US$60m Series C round of ExScientia Ltd, the world-leading artificial intelligence (AI)-driven drug discovery company.

Metabolic disease specialist Poxel SA has announced a private placement of 2,358,483 new ordinary shares at €0.02 per share reserved to specified investors.

The European Commission has taken up the European Council’s demand for deregulation of new plant breeding techniques (NBT). A new study is being conducted to form the basis for a campaign from the Commission to inform the public about the benefits of targeted mutation technologies and to break the resistance to genetically engineered crops.

Researchers at the University Oxford and AstraZeneca have started enrolment for a Phase II/III trial to test a COVID-19 vaccine in 10,000 volunteers.

From the beginning of July, Sarah Gordon Wild will be an Independent non-Executive Director at Redx Pharma in Alderley Park, UK.

An international research consortium provides data demonstrating that SARS-CoV-2 antibody tests are only useful for population-based analyses.
 

Two companies have presented a novel vaccination concept that might protect risk groups from new SARS-CoV-2 variants.